Pulmonary Arterial Hypertension
Pipeline by Development Stage
Drug Modality Breakdown
Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.
Key Trends
- FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
- SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
- Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure
Career Verdict
Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (Apixaban) | Bristol Myers Squibb | $18.3B | 26% | Peak | Stable | 15.0yr |
| 2 | JARDIANCE (Empagliflozin) | Boehringer Ingelheim | $8.8B | 13% | Peak | Growing | 8.6yr |
| 3 | XARELTO (Rivaroxaban) | Johnson & Johnson | $6.3B | 9% | Peak | Stable | |
| 4 | FARXIGA (Dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
| 5 | JANUVIA (Sitagliptin) | Merck & Co. | $4.1B | 6% | LOE_Approaching | Declining | 1.0yr |
Drug Class Breakdown
Mature, stable revenue base
Growing in heart failure and renal indications
Declining as LOE approaches 2027
Stable in heart failure management
Niche pulmonary hypertension market
Career Outlook
StableCardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.
Breaking In
Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.
For Experienced Professionals
Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.
In-Demand Skills
Best For
Hiring Landscape
Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.
Top Hiring Companies
By Department
Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.
On Market (7)
Approved therapies currently available
Competitive Landscape
49 companies ranked by most advanced pipeline stage
+19 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 7,986 patients across 50 trials
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
Treprostinil Combined With Tadalafil for Pulmonary Hypertension
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
Quality of Erection Study
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
QEQ Treatment Responsiveness Evaluation Study
Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction
Blood Pressure Interaction Between Sildenafil and Sublingual Glyceryl Trinitrate (GTN) in Men With Angina
A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate
A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
Inhaled Treprostinil for PAH: Open-label Extension
Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
Imatinib (QTI571) in Pulmonary Arterial Hypertension
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
A Study to Evaluate GSK1325760A - a Long-Term Extension Study
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
Related Jobs in Cardiovascular
Associate Director, Marketing - HCC
Associate Director, Marketing - HCC
Bölge Satış Müdürü, PAH
Sr. Pharmaceutical Info Specialist, PAH
Sr. Pharmaceutical Info Specialist, PAH
Sr. Specialist, Engineering (Onsite)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.